EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Parkinson's disease: use of piribedil



Treatment of Parkinson's disease: use of piribedil



Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(1): 54-56




(PDF 0-2 workdays service: $29.90)

Accession: 035980559

Download citation: RISBibTeXText

PMID: 14870695



Related references

Piribedil in the treatment of Parkinson disease. Rivista di Patologia Nervosa E Mentale 96(2): 103-110, 1975

Action of piribedil in Parkinson's disease: I.V. test and oral treatment. Advances in Neurology 9: 409-413, 1975

Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa. Acta Neurologica Scandinavica 52(3): 179-186, 1975

The agonist of dopamine receptors piribedil in treatment of Parkinson's disease. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 117(6): 83-90, 2017

Piribedil--an oral dopamine agonist for treatment of Parkinson's disease. Transactions of the American Neurological Association 99: 258-260, 1974

Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108(4): 49-55, 2008

Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson's Disease: A Meta-Analysis. Open Medicine 13: 270-277, 2018

Implication of piribedil (pronoran) in the treatment of Parkinson's disease: a clinical and pharmacoeconomic analysis. 2007

A multicenter trial of piribedil as early adjunct treatment for Parkinsons disease Piribedil international study group. Neurology 58(7 Supplement 3): A163, April 9, 2002

12-Month safety of piribedil as early adjunct treatment in Parkinsons disease Piribedil international follow-up Study. European Journal of Neurology 10(Supplement 1): 167, September, 2003

Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: A 6-month open study. Journal of the Medical Association of Thailand 87(11): 1293-1300, 2004

Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study. Journal of the Medical Association of Thailand 87(11): 1293-1300, 2005

From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacology & Therapeutics 128(2): 229-273, 2011

The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Movement Disorders 21(4): 500-509, 2005

Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. Cns Drugs 30(8): 703-717, 2016